Research output

Research output per year 1993 2010 2011 2012 2018 2022 2024

• 251 Article
• 145 Letter
• 38 Review article
• 10 Comment/debate
• 9 More
  • 4 Editorial
  • 3 Short survey
  • 2 Chapter

Research output per year

Research output per year

Search results

• 2024

  Advanced systemic mastocytosis—Revised classification, new drugs and how we treat

  Pardanani, A., Reichard, K. & Tefferi, A., Feb 2024, In: British journal of haematology. 204, 2, p. 402-414 13 p.

  Research output: Contribution to journal › Review article › peer-review

• Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant

  Tefferi, A., Pardanani, A., Begna, K. H., Al-Kali, A., Hogan, W., Litzow, M. R., Ketterling, R. P., Reichard, K. K. & Gangat, N., Dec 2024, In: Blood cancer journal. 14, 1, 51.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents

  Johnson, I. M., Karrar, O., Rana, M., Iftikhar, M., Chen, S., McCullough, K., Saliba, A. N., Al-Kali, A., Alkhateeb, H., Begna, K., Litzow, M., Hogan, W. J., Shah, M., Patnaik, M. M., Pardanani, A., Hermann, J., Tefferi, A. & Gangat, N., 2024, (Accepted/In press) In: British journal of haematology.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Acute Myeloid Leukemia 60%
  • Non-ST Elevated Myocardial Infarction 41%
  • Pericarditis 39%
  • Cardiomyopathies 30%

• Granularity in disease classification impacts survival prediction in advanced systemic mastocytosis: A single institution study of 329 informative cases

  Tefferi, A., Abdelmagid, M., Al-Kali, A., Patnaik, M., Hogan, W. J., Begna, K., Gangat, N., Orazi, A., Chen, D., Reichard, K. K. & Pardanani, A., Jan 2024, In: American journal of hematology. 99, 1, p. 21-27 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Mast-Cell Leukemia 100%
  • Systemic Mastocytosis 86%
  • Survival 32%
  • Hematologic Neoplasms 27%
  • Neoplasms 10%

• Incidental discovery of KIT-mutated mastocytoma in a colon polyp

  Gangat, N., McPhail, E., Reichard, K., Orazi, A., Pardanani, A. & Tefferi, A., May 2024, In: American journal of hematology. 99, 5, p. 973-974 2 p.

  Research output: Contribution to journal › Article › peer-review

• Mast cell cytomorphology and treatment outcome in mast cell leukemia

  Tefferi, A., Pardanani, A., Al-Kali, A., Alkhateeb, H., McCullough, K., Patnaik, M., Hogan, W. J., Begna, K., Elliott, M. A., Khera, N., Palmer, J. M., Gangat, N., Kelemen, K., Orazi, A., Chen, D. & Reichard, K. K., Jan 2024, In: American journal of hematology. 99, 1, p. E5-E8

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Molecular predictors of response and survival following IDH1/2 inhibitor monotherapy in acute myeloid leukemia

  Gangat, N., McCullough, K., Abdelmagid, M., Karrar, O., Powell, M., Al-Kali, A., Alkhateeb, H., Begna, K., Mangaonkar, A., Saliba, A., Torghabeh, M. H., Litzow, M., Hogan, W., Shah, M., Patnaik, M., Pardanani, A., Badar, T., Foran, J., Palmer, J., Sproat, L., & 2 othersYi, C. A. & Tefferi, A., Jan 2024, In: Haematologica. 109, 1, p. 287-292 6 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Momelotinib expands the therapeutic armamentarium for myelofibrosis: Impact on hierarchy of treatment choices

  Tefferi, A., Pardanani, A. & Gangat, N., Feb 2024, In: American journal of hematology. 99, 2, p. 300-308 9 p.

  Research output: Contribution to journal › Review article › peer-review

• Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval

  Tefferi, A. & Pardanani, A., Dec 2024, In: Blood cancer journal. 14, 1, 47.

  Research output: Contribution to journal › Editorial › peer-review

  Open Access

• One thousand patients with essential thrombocythemia: the Mayo Clinic experience

  Gangat, N., Karrar, O., Al-Kali, A., Begna, K. H., Elliott, M. A., Wolanskyj-Spinner, A. P., Pardanani, A., Hanson, C. A., Ketterling, R. P. & Tefferi, A., Dec 2024, In: Blood cancer journal. 14, 1, 11.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Essential Thrombocythemia 100%
  • cefotaxime syn S-oxide 80%
  • Survival 41%
  • Thrombosis 38%
  • Abnormal Karyotype 34%

• Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome

  Pardanani, A., Tefferi, A., Al-Kali, A., Patnaik, M., Hogan, W. J., Begna, K., Elliott, M. A., Khera, N., Palmer, J. M., Gangat, N., Orazi, A., Kelemen, K., Reichard, K. K. & Chen, D., Jan 2024, In: American journal of hematology. 99, 1, p. E1-E4

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients

  Gangat, N., Karrar, O., Iftikhar, M., McCullough, K., Johnson, I. M., Abdelmagid, M., Abdallah, M., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Mangaonkar, A., Saliba, A. N., Hefazi Torghabeh, M., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A., Badar, T., Murthy, H., & 6 othersForan, J., Palmer, J., Sproat, L., Khera, N., Arana Yi, C. & Tefferi, A., Feb 2024, In: American journal of hematology. 99, 2, p. 193-202 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • Acute Myeloid Leukemia 60%
  • Genotype 45%
  • Mutation 35%
  • Survival 34%

• Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

  Karrar, O., Abdelmagid, M., Rana, M., Iftikhar, M., McCullough, K., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Elliott, M. A., Mangaonkar, A., Saliba, A., Hefazi Torghabeh, M., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A., Badar, T., Murthy, H., Foran, J., & 6 othersPalmer, J., Sproat, L., Khera, N., Arana Yi, C., Tefferi, A. & Gangat, N., Feb 2024, In: American journal of hematology. 99, 2, p. E63-E66

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patients

  Nanaa, A., He, R., Foran, J. M., Badar, T., Gangat, N., Pardanani, A., Hogan, W. J., Litzow, M. R., Patnaik, M., Al-Kali, A. & Alkhateeb, H. B., Jan 2024, In: British journal of haematology. 204, 1, p. 171-176 6 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • venetoclax 100%
  • GATA2 Deficiency 87%
  • Acute Myeloid Leukemia 40%
  • B-Cell Leukemia 29%
  • Myelodysplastic Syndromes 23%
• 2023

  Abnormal karyotype is an independent predictor of inferior survival in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  Abdallah, M., McCullough, K., Ilyas, R., Begna, K. H., Al-Kali, A., Litzow, M. R., Hogan, W. J., Mangaonkar, A., Alkhateeb, H., Shah, M. V., Elliott, M. A., Foran, J. M., Badar, T., Palmer, J. M., Yi, C. A., Sproat, L., Pardanani, A., Patnaik, M. M., Olteanu, H., Ketterling, R. P., & 2 othersTefferi, A. & Gangat, N., Dec 2023, In: Blood cancer journal. 13, 1, 35.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Adverse karyotype subcategories in acute myeloid leukemia display significant differences in mutation composition and transplant-augmented survival

  Tefferi, A., Singh, A., Gangat, N., Al-Kali, A., Alkhateeb, H., Shah, M., Patnaik, M. S., Elliott, M. A., Hogan, W. J., Litzow, M. R., Wolanskyj-Spinner, A., Hook, C. C., Mangaonkar, A., Viswanatha, D., Chen, D., Pardanani, A., Begna, K. H. & Ketterling, R. P., Jan 2023, In: Haematologica. 108, 1, p. 245-249 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count

  Tefferi, A., Loscocco, G. G., Farrukh, F., Szuber, N., Mannelli, F., Pardanani, A., Hanson, C. A., Ketterling, R. P., De Stefano, V., Carobbio, A., Barbui, T., Guglielmelli, P., Gangat, N. & Vannucchi, A. M., Dec 2023, In: American journal of hematology. 98, 12, p. 1829-1837 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Essential Thrombocythemia 100%
  • Lymphocyte Count 80%
  • Neutrophils 58%
  • Abnormal Karyotype 25%
  • Lymphocytes 25%

• Black African-American patients with primary myelofibrosis: a comparative analysis of phenotype and survival

  Gangat, N., Kuykendall, A., Ali, N. A., Goel, S., Abdelmagid, M., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Mangaonkar, A., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A., Komrokji, R. & Tefferi, A., Jun 1 2023, In: Blood Advances. 7, 12, p. 2694-2698 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Blast phase myeloproliferative neoplasm with prior exposure to ruxolitinib: comparative analysis of mutations and survival

  Abdelmagid, M. G., Al-Kali, A., Begna, K. H., Hogan, W. J., Litzow, M. R., Fleti, F., Mangaonkar, A. A., Patnaik, M. S., Elliott, M. A., Alkhateeb, H., Shi, M., Howard, M. T., Reichard, K. K., Ketterling, R. P., Shah, M., Pardanani, A., Gangat, N. & Tefferi, A., Sep 2023, In: Haematologica. 108, 9, p. 2542-2545 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Bortezomib and daratumumab in refractory autoimmune hemolytic anemia

  McGlothlin, J., Abeykoon, J., Al-Hattab, E., Ashrani, A. A., Elliott, M., Hook, C. C., Pardanani, A., Pruthi, R., Sridharan, M., Wolanskyj, A., Rouse, R. & Go, R., Oct 2023, In: American journal of hematology. 98, 10, p. E263-E265

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases

  Ilyas, R., McCullough, K., Badar, T., Patnaik, M. M., Alkhateeb, H., Mangaonkar, A., Pardanani, A., Tefferi, A. & Gangat, N., Dec 2023, In: Blood cancer journal. 13, 1, 26.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor

  Gangat, N., Begna, K. H., Al-Kali, A., Hogan, W., Litzow, M., Pardanani, A. & Tefferi, A., Dec 2023, In: Blood cancer journal. 13, 1, 3.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • N,N-dicyclopropyl-4-((1,5-dimethyl-1H-pyrazol-3-yl)amino)-6-ethyl-1-methyl-1,6-dihydroimidazo(4,5-d)pyrrolo(2,3b)pyridine-7-carboxamide 100%
  • N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 82%
  • Fedratinib 82%
  • INCB018424 66%
  • Primary Myelofibrosis 53%

• Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis

  Tefferi, A., Pardanani, A. & Gangat, N., Nov 2023, In: Haematologica. 108, 11, p. 2919-2932 14 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 100%
  • Type I Activin Receptors 91%
  • Primary Myelofibrosis 64%
  • Janus Kinase Inhibitors 41%
  • Clinical Trials 33%

• Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy

  Gangat, N., Ilyas, R., Johnson, I. M., McCullough, K., Al-Kali, A., Alkhateeb, H. B., Begna, K. H., Mangaonkar, A., Litzow, M. R., Hogan, W., Shah, M., Patnaik, M. M., Pardanani, A. & Tefferi, A., Nov 2023, In: Haematologica. 108, 11, p. 3170-3174 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival

  Gangat, N., Begna, K. H., Al-Kali, A., Hogan, W., Litzow, M., Pardanani, A. & Tefferi, A., Feb 2023, In: American journal of hematology. 98, 2, p. 282-289 8 p.

  Research output: Contribution to journal › Article › peer-review

  • N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 100%
  • Primary Myelofibrosis 64%
  • Anemia 43%
  • Survival 28%
  • Mutation 17%

• Predictors of response to venetoclax plus hypomethylating agent therapy and survival in blast-phase myeloproliferative neoplasm

  Gangat, N., Ilyas, R., McCullough, K., Begna, K. H., Al-Kali, A., Patnaik, M. M., Litzow, M. R., Hogan, W. J., Mangaonkar, A., Alkhateeb, H., Shah, M. V., Elliott, M. A., Foran, J. M., Badar, T., Palmer, J. M., Hanson, C. A., Pardanani, A. & Tefferi, A., May 2023, In: Haematologica. 108, 5, p. 1423-1428 6 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Sodium-glucose co-transporter-2 inhibitor use and JAK2 unmutated erythrocytosis in 100 consecutive cases

  Gangat, N., Abdallah, M., Szuber, N., Saliba, A., Alkhateeb, H., Al-Kali, A., Begna, K. H., Pardanani, A. & Tefferi, A., Jul 2023, In: American journal of hematology. 98, 7, p. E165-E167

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management

  Pardanani, A., Jul 2023, In: American journal of hematology. 98, 7, p. 1097-1116 20 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Systemic Mastocytosis 100%
  • Risk Management 74%
  • Mast Cells 26%
  • Imatinib Mesylate 15%
  • Protein-Tyrosine Kinases 12%

• The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients

  Barbui, T., Carobbio, A., Thiele, J., Gangat, N., Rumi, E., Rambaldi, A., Vannucchi, A. M., Tefferi, A., Jeryczynski, G., Müllauer, L., Vaidya, R., Sulai, N. H., Pardanani, A., Larson, D. R., Cazzola, M., Casetti, I., Finazzi, G., Pieri, L., Gisslinger, H., Gisslinger, B., & 5 othersRodeghiero, F., Ruggeri, M., Randi, M. L., Bertozzi, I. & Passamonti, F., Dec 2023, In: Blood cancer journal. 13, 1, 187.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Polycythemia Vera 100%
  • Disease Progression 61%
  • Thrombosis 59%
  • Blast Crisis 23%
  • Venous Thrombosis 16%

• TP53 mutations and variant allele frequency in myelodysplastic syndromes with del(5q): A Mayo-Moffitt study of 156 informative cases

  Fleti, F., Chan, O., Singh, A., Abdelmagid, M. G., Al-Kali, A., Elliott, M. A., Begna, K. H., Foran, J. M., Badar, T., Khera, N., Al Ali, N. H., Padron, E., Sallman, D. A., Shah, M., Hiwase, D., Pardanani, A., Arber, D. A., Orazi, A., Reichard, K. K., He, R., & 4 othersKetterling, R. P., Gangat, N., Komrokji, R. & Tefferi, A., Apr 2023, In: American journal of hematology. 98, 4, p. E76-E79

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q)

  Tefferi, A., Fleti, F., Chan, O., Al Ali, N. H., Al-Kali, A., Begna, K. H., Foran, J. M., Badar, T., Khera, N., Shah, M., Hiwase, D., Padron, E., Sallman, D. A., Pardanani, A., Arber, D. A., Orazi, A., Reichard, K. K., He, R., Ketterling, R. P., Gangat, N., & 1 othersKomrokji, R., 2023, (Accepted/In press) In: British journal of haematology.

  Research output: Contribution to journal › Article › peer-review

  • Myelodysplastic Syndromes 100%
  • Gene Frequency 86%
  • Survival 49%
  • Allogeneic Cells 23%
  • Decision Making 18%
• 2022

  1.5 million platelet count limit at essential thrombocythemia diagnosis: Correlations and relevance to vascular events

  Gangat, N., Szuber, N., Jadoon, Y., Farrukh, F., Begna, K., Elliott, M. A., Wolanskyj-Spinner, A. P., Hanson, C. A., Pardanani, A. D., De Stefano, V., Barbui, T., Vannucchi, A. M. & Tefferi, A., Jul 12 2022, In: Blood Advances. 6, 13, p. 3835-3839 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy

  Tefferi, A., Gangat, N., Al-Kali, A., Alkhateeb, H., Shah, M., Patnaik, M. S., Elliott, M. A., Hogan, W. J., Litzow, M. R., Hook, C. C., Mangaonkar, A., Viswanatha, D., Chen, D., Pardanani, A., Ketterling, R. P., DiNardo, C. D., Kadia, T. M., Ravandi, F., Sasaki, K. & Begna, K. H., Sep 2022, In: American journal of hematology. 97, 9, p. 1127-1134 8 p.

  Research output: Contribution to journal › Article › peer-review

  • Induction Chemotherapy 100%
  • Acute Myeloid Leukemia 79%
  • Survival 46%
  • Karyotype 28%
  • Hematopoietic Stem Cells 27%

• Chronic phase CML with sole P190 (e1a2) BCR::ABL1: long-term outcome among ten consecutive cases

  Abdelmagid, M. G., Litzow, M. R., McCullough, K. B., Gangat, N., Pardanani, A., Murthy, H. S., Foran, J. M., Ketterling, R. P., Viswanatha, D., Begna, K. H. & Tefferi, A., Jul 2022, In: Blood cancer journal. 12, 7, 103.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Cladribine therapy for advanced and indolent systemic mastocytosis: Mayo Clinic experience in 42 consecutive cases

  Tefferi, A., Kittur, J., Farrukh, F., Begna, K. H., Patnaik, M. M., Al-Kali, A., Elliott, M. A., Reichard, K. K., Gangat, N. & Pardanani, A., Feb 2022, In: British journal of haematology. 196, 4, p. 975-983 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Systemic Mastocytosis 100%
  • Cladribine 99%
  • Mast-Cell Leukemia 14%
  • Therapeutics 11%
  • Tryptases 11%

• Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”

  Begna, K. H., Xu, X., Gangat, N., Alkhateeb, H., Patnaik, M. M., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Hook, C. C., Wolanskyj-Spinner, A. P., Mangaonkar, A., He, R., Pardanani, A., Shah, M., Ketterling, R. P. & Tefferi, A., Apr 2022, In: Blood cancer journal. 12, 4, 55.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases

  Gangat, N., Jadoon, Y., Szuber, N., Hanson, C. A., Wolanskyj-Spinner, A. P., Ketterling, R. P., Pardanani, A. & Tefferi, A., Mar 2022, In: Blood cancer journal. 12, 3, 44.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Essential Thrombocythemia 100%
  • Abnormal Karyotype 77%
  • Karyotype 75%
  • Chromosome Aberrations 72%
  • Mutation 31%

• Daunorubicin-60 versus daunorubicin-90 versus idarubicin-12 for induction chemotherapy in acute myeloid leukemia: a retrospective analysis of the Mayo Clinic experience

  Tefferi, A., Gangat, N., Shah, M., Alkhateeb, H., Patnaik, M. S., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Hook, C. C., Mangaonkar, A., Viswanatha, D., Chen, D., Pardanani, A., Ketterling, R. P. & Begna, K. H., Oct 2022, In: Haematologica. 107, 10, p. 2474-2479 6 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia

  Farrukh, F., Guglielmelli, P., Loscocco, G. G., Pardanani, A., Hanson, C. A., De Stefano, V., Barbui, T., Gangat, N., Vannucchi, A. M. & Tefferi, A., Feb 1 2022, In: American journal of hematology. 97, 2, p. E35-E37

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• Erythrocytosis associated with EPAS1(HIF2A), EGLN1(PHD2), VHL, EPOR or BPGM mutations: the Mayo Clinic experience

  Gangat, N., Oliveira, J. L., Porter, T. R., Hoyer, J. D., Al-Kali, A., Patnaik, M. M., Pardanani, A. & Tefferi, A., May 2022, In: Haematologica. 107, 5, p. 1201-1204 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access

• European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response

  Begna, K. H., Kittur, J., Gangat, N., Alkhateeb, H., Patnaik, M. S., Al-Kali, A., Elliott, M. A., Hogan, W. J., Litzow, M. R., Pardanani, A., Hanson, C. A., Ketterling, R. P. & Tefferi, A., Jan 2022, In: Blood cancer journal. 12, 1, 7.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Hematopoietic Stem Cells 100%
  • Acute Myeloid Leukemia 96%
  • Transplants 63%
  • Survival 31%
  • Karyotype 29%

• Jaktinib (JAK1/2 inhibitor): A momelotinib derivative with similar activity and optimized dosing schedule

  Tefferi, A., Gangat, N. & Pardanani, A., Dec 2022, In: American journal of hematology. 97, 12, p. 1507-1509 3 p.

  Research output: Contribution to journal › Editorial › peer-review

• Lenalidomide therapy for primary myelodysplastic syndromes with isolated del(5q): Determinants of response and survival in a real-world setting

  Singh, A., Al-Kali, A., Foran, J. M., Elliott, M. A., Begna, K., Badar, T., Khera, N., Fleti, F., Abdelmagid, M., Reichard, K. K., Ketterling, R. P., Pardanani, A., Gangat, N. & Tefferi, A., Oct 2022, In: American journal of hematology. 97, 10, p. E377-E379

  Research output: Contribution to journal › Letter › peer-review

• Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience

  Gangat, N., McCullough, K., Al-Kali, A., Begna, K. H., Patnaik, M. M., Litzow, M. R., Hogan, W., Shah, M., Alkhateeb, H., Mangaonkar, A., Foran, J. M., Palmer, J. M., Pardanani, A. & Tefferi, A., Aug 2022, In: British journal of haematology. 198, 4, p. e54-e58

  Research output: Contribution to journal › Letter › peer-review

• Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts

  Gangat, N., Chetram, D., McCullough, K., Al-Kali, A., Begna, K., Hogan, W., Litzow, M., Foran, J., Badar, T., Palmer, J., Patnaik, M., Pardanani, A. & Tefferi, A., Dec 2022, In: American journal of hematology. 97, 12, p. E474-E477

  Research output: Contribution to journal › Letter › peer-review

• Lymphocytopenia predicts shortened survival in myelodysplastic syndrome with ring sideroblasts (MDS-RS) but not in MDS/MPN-RS-T

  Mangaonkar, A. A., Farrukh, F., Reichard, K. K., Ketterling, R. P., Gangat, N., Al-Kali, A., Begna, K., Pardanani, A., Patnaik, M. M. & Tefferi, A., Mar 1 2022, In: American journal of hematology. 97, 3, p. E109-E112

  Research output: Contribution to journal › Letter › peer-review

• Mast cell sarcoma: 2 Mayo Clinic cases

  Singh, A., Alkhateeb, H., Pardanani, A., He, R., Orazi, A., Tefferi, A. & Reichard, K. K., Oct 2022, In: American journal of hematology. 97, 10, p. 1381-1383 3 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

• Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive cases

  Singh, A., Al-Kali, A., Begna, K. H., Litzow, M. R., Larsen, J. T., Sher, T., Abdelmagid, M. G., Farrukh, F., Reichard, K. K., Gangat, N., Pardanani, A. & Tefferi, A., May 2022, In: American journal of hematology. 97, 5, p. 630-637 8 p.

  Research output: Contribution to journal › Article › peer-review

  • midostaurin 100%
  • Systemic Mastocytosis 88%
  • Mast-Cell Leukemia 17%
  • Cladribine 14%
  • Tryptases 13%

• Midostaurin therapy for indolent and smoldering systemic mastocytosis: Retrospective review of Mayo Clinic experience

  Farrukh, F., Gangat, N., Shah, M. V., Litzow, M. R., Elliott, M. A., Begna, K., Hook, C. C., Tefferi, A. & Pardanani, A., Apr 2022, In: American journal of hematology. 97, 4, p. E138-E140

  Research output: Contribution to journal › Letter › peer-review

• Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia

  Gangat, N., Johnson, I., McCullough, K., Farrukh, F., Al-Kali, A., Alkhateeb, H., Begna, K., Mangaonkar, A., Litzow, M., Hogan, W., Shah, M., Patnaik, M., Pardanani, A. & Tefferi, A., Oct 2022, In: Haematologica. 107, 10, p. 2501-2505 5 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access